<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3390/pathogens9110928</dc:identifier><dc:language>eng</dc:language><dc:creator>Mullbacher, A.</dc:creator><dc:creator>Pardo, J.</dc:creator><dc:creator>Furuya, Y.</dc:creator><dc:title>SARS-CoV-2 vaccines: Inactivation by gamma irradiation for T and B cell immunity</dc:title><dc:identifier>ART-2020-121080</dc:identifier><dc:description>Despite accumulating preclinical data demonstrating a crucial role of cytotoxic T cell immunity during viral infections, ongoing efforts on developing COVID-19 vaccines are mostly focused on antibodies. In this commentary article, we discuss potential benefits of cytotoxic T cells in providing long-term protection against COVID-19. Further, we propose that gamma-ray irradiation, which is a previously tested inactivation method, may be utilized to prepare an experimental COVID-19 vaccine that can provide balanced immunity involving both B and T cells.</dc:description><dc:date>2020</dc:date><dc:source>http://zaguan.unizar.es/record/97169</dc:source><dc:doi>10.3390/pathogens9110928</dc:doi><dc:identifier>http://zaguan.unizar.es/record/97169</dc:identifier><dc:identifier>oai:zaguan.unizar.es:97169</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/DGA-FEDER/B29-17R</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/Fondo-COVID19</dc:relation><dc:relation>info:eu-repo/grantAgreement/ES/MCIU-AEI/SAF2017-83120-C2-1-R</dc:relation><dc:identifier.citation>Pathogens 9, 11 (2020), 928 [5 pp]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>